High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 201–300 of 960
Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Aravena, C., Gonzalo Labarca, T., Venegas, C., Arenas, Á., & Rada, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136160 · Cited by 84
“Unfortunately, previously used drugs (prednisone, azathioprine and N-acetyl cysteine among others) are nowadays discredited after the publication of trials that showed higher mortality rates and/or no improvement in slowing decline of lung function[3,26,27].”
BackgroundThe Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis
Pullamsetti, S. S., Savai, R., Dumitrascu, R., Dahal, B. K., Wilhelm, J., Königshoff, M., Zakrzewicz, D., Ghofrani, H. A., Weißmann, N., Eickelberg, O., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001725 · Cited by 82
Current and novel drug therapies for idiopathic pulmonary fibrosis
Maher, T. M., & Adamali, H. I. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s29928 · Cited by 90
“This was a doubleblind, randomized, multicenter study that assessed the effectiveness over 1 year of high-dose oral NAC (600 mg three times daily) together with prednisone and azathioprine compared to prednisone and azathioprine alone.(31) The pri-”
BackgroundDeterminants of initiation and progression of idiopathic pulmonary fibrosis
Kottmann, R. M., Hogan, C. M., Phipps, R. P., & Sime, P. J. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01624.x · Cited by 81
Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis
Antoniou, K. M., Pataka, A., Bouros, D. E., & Siafakas, N. M. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2006.01.002 · Cited by 76
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma
Hamblin, M. J., & Horton, M. R. (2011) · Pulmonary Medicine · doi:10.1155/2011/872120 · Cited by 83
“If there is evidence of reticular markings and honeycombing suggesting UIP, we still attempt a trial of immunosuppressive therapy as described above, but we also treat with N-acetylcysteine 600 mg three times daily based on clinical studies in idiopathic pulmonary fibrosis [81].”
InfluentialEndothelin in Pulmonary Fibrosis
Fonseca, C., Abraham, D., & Renzoni, E. A. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0388tr · Cited by 70
Sakamoto, S., Muramatsu, Y., Satoh, K., Ishida, F., Kikuchi, N., Sano, G., Sugino, K., Isobe, K., Takai, Y., & Homma, S. (2015) · Respirology · doi:10.1111/resp.12477 · Cited by 70
Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs
Hadjicharalambous, M. R., & Lindsay, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020524 · Cited by 75
“The IFIGENIA trial, a double-blind, randomized, placebo-controlled study assessed the efficacy of N-acetylcysteine (NAC) added to prednisone and azathioprine [37], however the survival benefit of IPF patients was questioned.”
MethodAssessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis
Peikert, T., Daniels, C. E., Beebe, T. J., Meyer, K. C., & Ryu, J. H. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.03.018 · Cited by 76
Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis
Crestani, B., Besnard, V., & Boczkowski, J. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.04.003 · Cited by 72
Taddei, M. L., Giannoni, E., Raugei, G., Scacco, S., Sardanelli, A. M., Papa, S., & Chiarugi, P. (2012) · Journal of Signal Transduction · doi:10.1155/2012/684592 · Cited by 72
“Indeed, oxidative stress, caused by increase in ROS is closely associated with fibrosis [40] and inhibitors of ROS have shown promise in clinical trials targeting this disease [41–43].”
BackgroundThe current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis
Kaarteenaho, R. L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-43 · Cited by 82
“The percentages of the SLBs were similar in the IFIGENIA and also in the first large interferon-study [26,27].”
ResultComprehensive care of the patient with idiopathic pulmonary fibrosis
Lee, J. S., McLaughlin, S., & Collard, H. R. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349721b · Cited by 80
Purinergic signaling in scarring
Ferrari, D., Gambari, R., Idzko, M., Müller, T., Albanesi, C., Pastore, S., Manna, G. L., Robson, S. C., & Cronstein, B. N. (2015) · The FASEB Journal · doi:10.1096/fj.15-274563 · Cited by 78
“Although the persistence of inciting pathologic agents and the consequent chronic inflammatory state have been suggested to beprerequisites todifferent formsofpulmonaryfibrosis, the situation is likely to bemore complex for IPF, because of the poor efficacy of standard anti-inflammatory therapies, including corticoste…”
BackgroundLung extracellular matrix and redox regulation
Watson, W. H., Ritzenthaler, J. D., & Roman, J. (2016) · Redox Biology · doi:10.1016/j.redox.2016.02.005 · Cited by 76
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Pitre, T., Mah, J. C., Helmeczi, W., Khalid, M. F., Cui, S., Zhang, M., Husnudinov, R., Su, J. S., Banfield, L. E., Guy, B., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217976 · Cited by 72
Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis
Tanaka, K., Ishihara, T., Azuma, A., Kudoh, S., Ebina, M., Nukiwa, T., Sugiyama, Y., Tasaka, Y., Namba, T., Ishihara, T., et al. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00289.2009 · Cited by 72
“In fact, administration of N-acetylcysteine (NAC), which stimulates the synthesis of glutathione, exhibited therapeutic effects on IPF patients and bleomycin-induced pulmonary fibrosis in animals (10, 30, 31, 39).”
BackgroundPirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial
Sakamoto, S., Kataoka, K., Kondoh, Y., Kato, M., Okamoto, M., Mukae, H., Bando, M., Suda, T., Yatera, K., Tanino, Y., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00348-2020 · Cited by 67
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martinez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 68
“Although exploratory, this early look at the potential interaction between genetics and therapeutic efficacy could explain discordant clinical trial results regarding the efficacy of NAC therapy in IPF (45, 66) and should prompt future clinical trials to include pharmacogenomic analyses in their study design.”
ResultUpdate on therapeutic management of idiopathic pulmonary fibrosis
Spagnolo, P., Τzouvelekis, Α., & Bonella, F. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s69716 · Cited by 78
“IFIGENIA, a double-blind, randomized, placebo-controlled multicenter study, assessed the efficacy over one year of a high oral dose of NAC (600 mg three times daily) in combination with prednisone and azathioprine.(24) While this so-called “triple therapy” significantly slowed the decline of both vital capacity and DL…”
Rosato, E., Borghese, F., Pisarri, S., & Salsano, F. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1251-7 · Cited by 67
“Acetylcysteine, added to standard therapy, in patients with idiopathic pulmonary fibrosis preserves vital capacity and DLco in patients with idiopathic pulmonary fibrosis [16].”
BackgroundDyspnea in Idiopathic Pulmonary Fibrosis: A Systematic Review
Ryerson, C. J., Donesky, D., Pantilat, S. Z., & Collard, H. R. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.04.026 · Cited by 76
Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model
Wuyts, W. A., Willems, S., Vos, R., Vanaudenaerde, B. M., Vleeschauwer, S. I. D., Rinaldi, M., Vanhooren, H. M., Geudens, N., Verleden, S. E., Demedts, M., et al. (2010) · Experimental Lung Research · doi:10.3109/01902148.2010.492895 · Cited by 71
“The only therapy that has shown to reduce pulmonary function decline is the addition of N-acetylcysteine to standard therapy [4].”
BackgroundSelf-citationIntegrin β 1: A Mechanosignaling Sensor Essential for Connective Tissue Deposition by Fibroblasts
Leask, A. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0365 · Cited by 67
Into the matrix: targeting fibroblasts in pulmonary fibrosis
Sivakumar, P., Ntolios, P., Jenkins, G., & Laurent, G. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356800f · Cited by 67
“N-acetylcysteine (NAC), a mucolytic drug with antioxidant properties, was shown to reduce the forced vital capacity (FVC) decline rate when used in combination triple therapy with prednisone and azathioprine [44].”
BackgroundIdiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations
Jo, H. E., Randhawa, S., Corte, T. J., & Moodley, Y. P. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0366-1 · Cited by 79
German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2018) · Pneumologie · doi:10.1055/s-0043-123035 · Cited by 71
Self-citationWells, A. U. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202640 · Cited by 69
Schmidt, S. L., Sundaram, B., & FLAHERTY, K. R. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01626.x · Cited by 72
Update in idiopathic pulmonary fibrosis
Frankel, S. K., & Schwarz, M. I. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32832ea4b3 · Cited by 72
The treatment of idiopathic pulmonary fibrosis
Woodcock, H. V., & Maher, T. M. (2014) · F1000Prime Reports · doi:10.12703/p6-16 · Cited by 74
“2005 [9], was the first RCT in IPF to achieve its primary”
BackgroundCottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.017 · Cited by 69
Self-citationGhanei, M., Shohrati, M., Jafari, M., Ghaderi, S., Alaeddini, F., & Aslani, J. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00318.x · Cited by 62
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Maher, T. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00000913 · Cited by 63
Martínez, F. J. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200511-123jh · Cited by 68
Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
Maher, T. M. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.002 · Cited by 70
New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Ding, Q., Luckhardt, T., Hecker, L., Zhou, Y., Liu, G., Antony, V. B., deAndrade, J. A., & Thannickal, V. J. (2011) · Drugs · doi:10.2165/11591490-000000000-00000 · Cited by 69
“IFIGENIA([18]) Pred/Aza –NAC FVC £80, DLCO <80 Absolute DFVC, DLCO 182 Yes Less deterioration in FVC”
BackgroundMethodInfluentialAnti-inflammatory mediators as physiological and pharmacological regulators of parturition
Rinaldi, S. F., Hutchinson, J. L., Rossi, A. G., & Norman, J. E. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.58 · Cited by 66
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Vancheri, C., & du Bois, R. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00115112 · Cited by 64
The dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice
Boots, A. W., Veith, C., Albrecht, C., Bartholomé, R., Drittij-Reijnders, M.-J., Claessen, S. M. H., Bast, A., Rosenbruch, M., Jonkers, L., van Schooten, F., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1142-x · Cited by 64
Oxidative stress and antioxidants in interstitial lung disease
Bast, A., Weseler, A. R., Haenen, G. R. M. M., & den Hartog, G. J. M. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32833c645d · Cited by 64
Review: Therapies for interstitial lung disease: past, present and future
Kim, R., & Meyer, K. C. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096948 · Cited by 66
Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis
Sakamoto, S., Itoh, T., Muramatsu, Y., Satoh, K., Ishida, F., Sugino, K., Isobe, K., & Homma, S. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8498 · Cited by 59
“In a review of NAC trials, a placebo-controlled randomized trial comparing the effects of high-dose oral acetylcysteine versus a placebo in patients receiving prednisone plus azathioprine has been completed (10).”
BackgroundEfficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis
Sun, T., Liu, J., & Zhao, D. W. (2016) · Medicine · doi:10.1097/md.0000000000003629 · Cited by 59
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 65
Wong, K. K., Lee, S. W. H., & Kua, K. P. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s306849 · Cited by 65
Interstitial lung disease in systemic sclerosis
Wells, A. U. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.08.002 · Cited by 63
Oxidative Damage and Antioxidative Therapy in Systemic Sclerosis
Grygiel‐Górniak, B., & Puszczewicz, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/389582 · Cited by 65
“In consequence, the numbers of tyrosine-phosphorylated proteins are diminished, the level of type I collagen is reduced, and the fibroblast proliferation is decreased [20, 68, 70, 71].”
BackgroundHisamoto, S., Shimoda, S., Harada, K., Iwasaka, S., Onohara, S., Chong, Y., Nakamura, M., Bekki, Y., Yoshizumi, T., Ikegami, T., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.08.006 · Cited by 57
Iron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage?
Puxeddu, E., Comandini, A., Cavalli, F., Pezzuto, G., D'Ambrosio, C., Senis, L., Paci, M., Curradi, G., Sergiacomi, G. L., & Saltini, C. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.12.002 · Cited by 57
“Anti-oxidants have been shown to dampen lung oxidative stress both when aerosolized [4] and administered systemically [32], as shown by the Ifigenia trial, demonstrating the efficacy of systemic anti-oxidant treatment added onto standard immunosuppressive therapy [7].”
BackgroundLi, S., Yang, X., Li, W., Li, J., Su, X., Chen, L., & Yan, G. (2012) · Respiration · doi:10.1159/000340041 · Cited by 56
Kim, A., Yu, H. Y., Heo, J., Song, M., Shin, J. H., Lim, J., Yoon, S.-J., Kim, Y., Lee, S., Kim, S. W., et al. (2016) · Scientific Reports · doi:10.1038/srep30881 · Cited by 58
Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
Mokrá, D., Mokrý, J., Barošová, R., & Hanusrichterová, J. (2023) · Antioxidants · doi:10.3390/antiox12091713 · Cited by 67
“For instance, the effectiveness of NAC (oral dose of 600 mg three times daily over one year) for IPF was evaluated in the IFIGENIA trial (NCT00639496) where three-drug therapy with NAC added to prednisone and azathioprine was more effective than the standard therapy with prednisone plus azathioprine [5].”
Safety and Tolerability of Inhaled Heparin in Idiopathic Pulmonary Fibrosis
Markart, P., Nass, R., Ruppert, C., Hundack, L., Wygrecka, M., Korfei, M., Boedeker, R. H., Staehler, G., Kroll, H., Scheuch, G., et al. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0780 · Cited by 56
The mitochondria in lung fibrosis: friend or foe?
Malsin, E. S., & Kamp, D. W. (2018) · Translational research · doi:10.1016/j.trsl.2018.05.005 · Cited by 58
Interstitial lung disease: progress and problems
Bourke, S. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.046417 · Cited by 56
Workshop on Idiopathic Pulmonary Fibrosis in Older Adults
Castriotta, R. J., Eldadah, B. A., Foster, W. M., Halter, J. B., Hazzard, W. R., Kiley, J. P., King, T. E., Horne, F. M., Nayfield, S., Reynolds, H. Y., et al. (2010) · CHEST Journal · doi:10.1378/chest.09-3006 · Cited by 61
Jin, J., Lv, X., Chen, L., Zhang, W., Li, J., Wang, Q., Wang, R., Lü, X., & Miao, D. (2014) · Aging Cell · doi:10.1111/acel.12236 · Cited by 55
“In clinical trials, NAC improves lung function in patients with chronic obstructive pulmonary disease, highlighting the potential benefit of ROS-directed therapy (Demedts et al., 2005).”
BackgroundRetractedAnti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression
Eberlein, M. H., Scheibner, K. A., Black, K. E., Collins, S. L., Chan‐Li, Y., Powell, J. D., & Horton, M. R. (2008) · Journal of Inflammation · doi:10.1186/1476-9255-5-20 · Cited by 63
“Paterson RL, G H, Webster NR: The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis.”
BackgroundMethodInfluentialJo, H. E., Troy, L. K., Keir, G. J., Chambers, D. C., Holland, A. E., Goh, N. S. L., WILSHER, M. L., de Boer, S., Moodley, Y. P., Grainge, C., et al. (2017) · Respirology · doi:10.1111/resp.13146 · Cited by 61
A New Hope for Idiopathic Pulmonary Fibrosis
Hunninghake, G. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1403448 · Cited by 57
Bmi1 regulates auditory hair cell survival by maintaining redox balance
Chen, Y., Li, H., Ni, W., Zhang, Y., Sun, S., Miao, D., Chai, R., & Li, H. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.549 · Cited by 54
“chronic obstructive pulmonary disease, highlighting the potential benefit of ROS-directed therapy.(53) In the current”
BackgroundPirfenidone: significant treatment effects in idiopathic pulmonary fibrosis
Hilberg, O., Simonsen, U., du Bois, R. M., & Bendstrup, E. M. (2012) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2012.00302.x · Cited by 60
“the combination of corticosteroids, the immunosuppressant azathioprine and the antioxidant N-acetylcysteine that was shown to slow progression in one study (34) [must now be viewed with some caution (28) after interim results from the IPFnet PANTHER study, disclosed only in a press release thus far, reported increased…”
ResultGorshkova, I., Zhou, T., Mathew, B., Jacobson, J. R., Takekoshi, D., Bhattacharya, P., Smith, B., Aydogan, B., Weichselbaum, R. R., Natarajan, V., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m026039 · Cited by 54
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
Spagnolo, P., Tonelli, R., Cocconcelli, E., Stefani, A., & Richeldi, L. (2012) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-7-42 · Cited by 59
“Conversely, treatments initially thought to slow the decline of lung function [46] or reduce mortality in patients experiencing acute exacerbation [47] and which received a weak recommendation against their use by the most recent guidelines [1] have subsequently been shown not only to be ineffective but even harmful i…”
BackgroundLung Involvement in Primary Sjögren's Syndrome—An Under-Diagnosed Entity
Sogkas, G., Hirsch, S., Olsson, K. M., Hinrichs, J. B., Thiele, T., Seeliger, T., Skripuletz, T., Schmidt, R. E., Witte, T., Dopfer‐Jablonka, A., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00332 · Cited by 56
Novelli, F., Neri, T., Tavanti, L. M., Armani, C., Noce, C., Falaschi, F., Bartoli, M. L., Martino, F., Palla, A., Celi, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095013 · Cited by 66
“Indeed, high dose NAC appears to preserve vital capacity and DLCO in IPF patients [36].”
BackgroundAli, S. A., Saifi, M. A., Pulivendala, G., Godugu, C., & Talla, V. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.111980 · Cited by 56
Markart, P., Luboeinski, T., Korfei, M., Schmidt, R., Wygrecka, M., Mahavadi, P., Mayer, K., Wilhelm, J., Seeger, W., Günther, A., et al. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2105 · Cited by 59
“In humans, a beneficial effect on the progression of IPF has been observed by the addition of N - acetylcysteine to standard therapy with prednisone and azathioprine (12).”
Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease
Kelly, C. A., & Saravanan, V. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802591430 · Cited by 55
“1 N-acetylcysteine N -acetylcysteine in the dose of 600 mg tds is effective at mopping up free oxygen radicals and has been shown to be effective in the treatment of idiopathic pulmonary fibrosis, in reducing the rate of decline in pulmonary function [46] .”
BackgroundLoveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-63 · Cited by 52
“2012 [20] Mean Age: 68 years Primary outcomes: absolute change in FVC at 48 weeks Unclear risk”
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
Antoniou, K. M., Margaritopoulos, G. A., & Siafakas, N. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00002113 · Cited by 53
Radomska-Leśniewska, D. M., Skopińska-Różewska, E., Jankowska-Steifer, E. A., Sobiecka, M., Sadowska, A. M., Hevelke, A., & Malejczyk, J. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70250-4 · Cited by 52
Ourique, A. F., Chaves, P. D. S., Souto, G. D., Pohlmann, A. R., Guterres, S. S., & Beck, R. C. R. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.09.017 · Cited by 54
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Cottin, V. (2012) · European Respiratory Review · doi:10.1183/09059180.00001112 · Cited by 59
Apoptosis and the Airway Epithelium
White, S. R. (2011) · Journal of Allergy · doi:10.1155/2011/948406 · Cited by 75
“has but modest benefit in these patients [208, 209].”
BackgroundPostoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer
Watanabe, A., Kawaharada, N., & Higami, T. (2011) · Pulmonary Medicine · doi:10.1155/2011/960316 · Cited by 52
“as macrolides [34, 35], N-acetylcysteine [36–39], proteinase”
Baldi, B. G., Pereira, C. A. D. C., Rubin, A. S., Santana, A. N. C., Costa, A. N., de Carvalho, C. R. R., Algranti, E., Capitani, E. M. D., Bethlem, E. P., Coletta, E. N. A. M., et al. (2012) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132012000300002 · Cited by 65
Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis
Margaritopoulos, G. A., Romagnoli, M., Poletti, V. E., Siafakas, N. M., Wells, A. U., & Antoniou, K. M. (2012) · European Respiratory Review · doi:10.1183/09059180.00007611 · Cited by 55
Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.12.011 · Cited by 58
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
Fleetwood, K., McCool, R., Glanville, J., Edwards, S. C., Gsteiger, S., Daigl, M., & Fisher, M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s5 · Cited by 49
Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis
Watanabe, A., Miyajima, M., Mishina, T., Nakazawa, J., Harada, R., Kawaharada, N., & Higami, T. (2012) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-012-0180-6 · Cited by 53
Wang, D., Yan, Z., Bu, L., An, C., Deng, B., Zhang, J., Rao, J., Lu, C. Y., Zhang, J., Zhang, B., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114703 · Cited by 55
Kalluri, M., Luppi, F., Vancheri, A., Vancheri, C., Balestro, E., Varone, F., Moğulkoç, N., Cacopardo, G., Bargagli, E., Renzoni, E. A., et al. (2021) · European Respiratory Review · doi:10.1183/16000617.0026-2021 · Cited by 55
Redox-Based Therapeutics for Lung Diseases
Hoshino, Y., & Mishima, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1961 · Cited by 48
“A study demonstrated that NAC treatment slows disease progression of IPF (4).”
T-cell and B-cell signaling biomarkers and treatment targets in lupus
Perl, A., Fernández, D., Caza, T. N., Doherty, E. H., Francis, L., & Phillips, P. E. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832e977c · Cited by 55
Idiopathic pulmonary fibrosis: Early detection and referral
Oldham, J. M., & Noth, I. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.03.008 · Cited by 59
“The NAC and placebo arms of this trial are ongoing to investigate whether NAC leads to a smaller decline in lung function in patients with IPF, as suggested by previous studies [87,88].”
Serum biomarkers in idiopathic pulmonary fibrosis
van den Blink, B., Wijsenbeek, M. S., & Hoogsteden, H. C. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.08.001 · Cited by 48
Antifibrotic effect of captopril and enalapril on paraquat‐induced lung fibrosis in rats
Ghazi‐Khansari, M., Mohammadi‐Karakani, A., Sotoudeh, M., Mokhtary, P., Pour‐Esmaeil, E., & Maghsoud, S. (2007) · Journal of Applied Toxicology · doi:10.1002/jat.1212 · Cited by 48
“…several studies have suggested a beneficial effect of antioxidant treatments in the amelioration of pulmonary fibrosis (Lasky and Ortiz, 2001; Demedts et al., 2005; Kuwano et al., 2001; Ghazi-Khansari et al., 2005) and paraquat-induced pulmonary lesions (Suntres, 2002), the results of the…”
BackgroundIdiopathic Pulmonary Fibrosis: New Concepts in Pathogenesis and Implications for Drug Therapy
Horowitz, J. C., & Thannickal, V. J. (2006) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200605050-00004 · Cited by 52
“[239] In inflammatory response without a decrease in lung hydroxyproline this study, 182 patients were randomized to receive oral NAC content following intratracheal bleomycin, suggesting that the (300mg three times daily) or placebo in addition to prednisone and absence of TNFα may not, in itself, attenuate the fibro…”
Pirfenidone for the treatment of idiopathic pulmonary fibrosis
Antoniu, S. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.823 · Cited by 51
“In a Phase III clinical study in IPF patients, it was shown demonstrated that N-acetylcysteine plus prednisone and azathioprine (conventional therapy) for 12 months did not improve survival, clinical–radiological–physiological scores, health-related quality of life, dyspnoea, radiological scores or exercise capacity,…”
ResultEndoplasmic reticulum stress and glutathione therapeutics in chronic lung diseases
Janssen-Heininger, Y. M. W., Reynaert, N. L., van der Vliet, A., & Anathy, V. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101516 · Cited by 48
Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts
Tsou, P., Talia, N. N., Pinney, A. J., Kendzicky, A., Piera-Velázquez, S., Jiménez, S. A., Seibold, J. R., Phillips, K., & Koch, A. E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.34336 · Cited by 50
“NAC is also used as a treatment for idiopathic pulmonary fibrosis (24).”
Highlights of HRCT imaging in IPF
Sverzellati, N. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s3 · Cited by 48
“In drug trial setting HRCT is the main tool to assess in vivo the morphologic response to treatment [5,7].”
MethodPodolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02281-8 · Cited by 52
“Therapy with NAC at 600 mg three times daily added to prednisone and azathioprine slowed the decline in FVC and single-breath carbon monoxide diffusing capacity (DLCO) at one year [10].”
Ferguson, H. E., Thatcher, T. H., Olsen, K. C., García-Bates, T. M., Baglole, C. J., Kottmann, R. M., Strong, E., Phipps, R. P., & Sime, P. J. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00148.2009 · Cited by 51
Mitra, S., Kundu, S., Ganguly, J., Mukherjee, S., Ray, S., & Mitra, R. (2014) · Lung India · doi:10.4103/0970-2113.142115 · Cited by 50
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.